US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

X4 Pharmaceuticals, Inc. - Common Stock (NQ:XFOR)

3.240 +0.040 (+1.25%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about X4 Pharmaceuticals, Inc. - Common Stock

News headline image
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
From X4 Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
From X4 Pharmaceuticals
Via GlobeNewswire
News headline image
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From X4 Pharmaceuticals
Via GlobeNewswire
Undervalued Stocks to Watch After X4 Pharma (NASDAQ:XFOR) News: KAVL, HNRC, AYRO, VVPR
Via AB Newswire
News headline image
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
From X4 Pharmaceuticals
Via GlobeNewswire
News headline image
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From X4 Pharmaceuticals
Via GlobeNewswire
News headline image
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
From X4 Pharmaceuticals
Via GlobeNewswire
News headline image
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
From X4 Pharmaceuticals
Via GlobeNewswire
News headline image
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
From X4 Pharmaceuticals
Via GlobeNewswire
News headline image
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
From X4 Pharmaceuticals
Via GlobeNewswire
News headline image
Mag 7 Stocks Under $5 Stocks: ATNF RMBL LOOP XFOR – Breakout Setups – More Stocks Inside
Via AB Newswire
Topics Earnings